BDBM387821 N-(2-Cyanoethyl)-2-(1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)acetamide::US10294226, Compound Ex. 4::US10487083, Example 4::US10981911, Example 4::US11059823, Example 4

SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCCC#N

InChI Key InChIKey=DZYJQAKCPQYEKD-UHFFFAOYSA-N

Data  22 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 22 hits for monomerid = 387821   

TargetNon-receptor tyrosine-protein kinase TYK2/Tyrosine-protein kinase JAK1(Human)
Janssen Research and Development

Curated by ChEMBL
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 65nMAssay Description:Inhibition of JAK1/Tyk2 in human PBMC assessed as reduction in IFNalpha-induced STAT4 phosphorylation pre-incubated for 30 mins before IFNalpha stimu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 96.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 6.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 96.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 6.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 6.60nMAssay Description:Inhibition of JAK2-JH1/JH2 domain (532 to 1132 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 90nMAssay Description:Inhibition of JAK2/JAK2 in human PBMC assessed as reduction in GM-CSF-induced STAT5 phosphorylation pre-incubated for 30 mins before GM-CSF stimulati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.100nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 96nMAssay Description:Inhibition of JAK3-JH1/JH2 domain (512 to 1124 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.140nMAssay Description:Inhibition of JAK1-JH1/JH2 domain (574 to 1154 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetJAK3/JAK1(Human)
Janssen Research and Development

Curated by ChEMBL
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 36nMAssay Description:Inhibition of JAK1/JAK3 in human PBMC assessed as reduction in IL2-induced STAT5 phosphorylation pre-incubated for 30 mins before IL2 stimulation for...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 96.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 6.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 2.20nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 96.2nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(US10294226, Compound Ex. 4 | N-(2-Cyanoethyl)-2-(1...)
Affinity DataIC50: 6.60nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent